International pharmaceutical group Mundipharma has concluded adistribution agreement with Laboratorios Columbia of Mexico, which will market the world's most widely-used controlled-release morphine, MST Continus tablets in Mexico, as well as the companion immediate-release product.
Under the terms of the agreement, Laboratorios Columbia will have the exclusive right to sell and distribute various strengths of twice-daily MST Continus tablets, once-daily Emexel Continus tablets, and immediate-release MSIR tablets thoughout Mexico.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze